# SLV-154

Source: https://onco.cc/drugs/slv-154/  
OnCo record `slv-154` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

SLV-154 is an experimental antibody-drug conjugate from Solve Therapeutics, in phase 1 trials for advanced solid tumours.

## Summary

SLV-154 is an antibody-drug conjugate from Solve Therapeutics. An antibody-drug conjugate combining a selective targeting antibody, the company's hydrophilic CloakLink linker and a potent cytotoxic payload, aimed at a membrane receptor protein on solid tumours that the company has not named. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06771219 recruiting. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: SLV-154
- Modality: Antibody-drug conjugate
- Mechanism: An antibody-drug conjugate combining a selective targeting antibody, the company's hydrophilic CloakLink linker and a potent cytotoxic payload, aimed at a membrane receptor protein on solid tumours that the company has not named.

## Sources

- Solve Therapeutics: solvetx.com: https://solvetx.com/
- Solve Therapeutics: solvetx.com: https://solvetx.com/
- Solve Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT06771219
- ClinicalTrials.gov: trials of SLV-154: https://clinicaltrials.gov/search?intr=SLV-154

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Solve Therapeutics](https://onco.cc/companies/solve-therapeutics/)
- trials: [SLV-154 Treatment of Advanced Cancers](https://onco.cc/trials/nct06771219/)

---
JSON: https://onco.cc/api/v1/entities/slv-154.json